The Health Disparities Advisory Group is focused on developing resources related to data and formulary and utilization management solutions that can close the gap on disparities in medication use. This advisory group is active from March 2022-February 2023.
The Digital Therapeutics Advisory Group is focused on developing resources for payers on when they should evaluate products, what manufacturers should communicate, and understanding how Digital Therapeutics are included in drug compendia. This advisory group is active from March 2022-February 2023.
The Biosimilars Operational Readiness group is an initiative focused on developing resources to aid in the assessment and implementation of biosimilars when formulary coverage is approved. This group launched in Q4 2022.
Partnership Forum: This forum helped identify payer needs and current barriers that payer currently face regarding evidence for therapies approved through an expedited approval process. In addition, participants identified potential solutions to address evidence gaps.
November 2022 Legislative & Regulatory Briefing; The PIE Act of 2022 Reintroduced with Bipartisan Support; Member Benefit! Catch Up on the Latest Regulatory NewsBREAKs; CMS Hiring for IRA Implementation; AMCP's Jennifer Mathieu Selected as a Top 20 in 2022 by The Advocacy Association; AMCP Makes Its Voice Heard, Submits Comments on Simplified Enrollment for Medicaid, CHIP, and Basic Health Programs; Now Open: Nominate an Individual for AMCP's Advocate of the Year Award.
Partnership Forum: The purpose of the forum was to identify concerns for high-investment medications related to predictability, affordability, and accessibility. Participants also explored alternative payments, financial tools, and policy initiatives related to these medications.
Congratulations to Zachary Brunko, PharmD candidate at the University of Minnesota College of Pharmacy, for completing AMCP Foundation’s first inaugural internship devoted to addressing health inequities.